Prediction of tissue-of-origin of early stage cancers using serum miRNomes.
Matsuzaki J, Kato K, Oono K, Tsuchiya N, Sudo K, Shimomura A, Tamura K, Shiino S, Kinoshita T, Daiko H, Wada T, Katai H, Ochiai H, Kanemitsu Y, Takamaru H, Abe S, Saito Y, Boku N, Kondo S, Ueno H, Okusaka T, Shimada K, Ohe Y, Asakura K, Yoshida Y, Watanabe SI, Asano N, Kawai A, Ohno M, Narita Y, Ishikawa M, Kato T, Fujimoto H, Niida S, Sakamoto H, Takizawa S, Akiba T, Okanohara D, Shiraishi K, Kohno T, Takeshita F, Nakagama H, Ota N, Ochiya T; Project Team for Development and Diagnostic Technology for Detection of miRNA in Body Fluids.
Matsuzaki J, et al.
JNCI Cancer Spectr. 2023 Jan 3;7(1):pkac080. doi: 10.1093/jncics/pkac080.
JNCI Cancer Spectr. 2023.
PMID: 36426871
Free PMC article.
The training set comprised 7931 serum samples from patients with 13 types of solid cancers and 5013 noncancer samples. ...Assessment of tissue expression patterns of these miRNAs suggested that miRNAs secreted from the tumor environment could be used to establish cancer ty …
The training set comprised 7931 serum samples from patients with 13 types of solid cancers and 5013 noncancer samples. ...Assessment …